Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies
07 Agosto 2023 - 2:05PM
Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial
Biology Company®, today announced a momentous achievement -
publication of the 1,000th peer-reviewed article citing use of the
company’s technology, the largest publication volume in the
industry. Approximately 80% of these articles have been published
in the last 2.5 years, reflecting the exponential growth in
adoption of Akoya's solutions.
As a trailblazer in spatial biology, Akoya is dedicated to
developing cutting-edge technologies that transform the
understanding of complex biological systems, empowering researchers
around the world to reveal unprecedented insights into cellular
behavior and disease mechanisms.
While the majority of publications have focused on oncology,
other areas of research include inflammatory disease, neuroscience,
and infectious diseases. Of note, several seminal papers were
recently published in Nature led by the Human BioMolecular Atlas
Program (HuBMAP), a National Institutes of Health (NIH) funded
consortium, and the Human Breast Cell Atlas Initiative supported by
numerous leading institutions and consortia. These papers presented
atlases of the human intestine, breast, and other organs created
with the use of several advanced technologies, including Akoya’s
PhenoCycler® platform. Akoya's platform was the central spatial
biology solution used for the discovery of key proteins and cell
types to identify spatial tissue domains that provide insight into
tissue architecture.
"Reaching this milestone of 1,000 publications is a testament to
the game-changing capabilities of Akoya's spatial biology
solutions," said Dr. Arutha Kulasinghe, Head of the Clinical-oMx
Lab at the University of Queensland, Australia. "The ability to
visualize how individual cells communicate in disease models has
been revolutionary for our research. Akoya's technology has
provided us with a new level of understanding, opening up exciting
possibilities for advancing drug discovery and precision
medicine."
"Our team is thrilled to celebrate the achievement of 1,000
publications," said Brian McKelligon, CEO of Akoya Biosciences. "We
are humbled by the trust the scientific community has placed in our
technology, and we are excited to continue advancing discovery in
spatial biology."
This milestone comes on the heels of the announcement in April
2023 that Akoya had shipped its 1,000th instrument,
representing the largest installed base in the spatial biology
industry.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is
to bring context to the world of biology and human health through
the power of spatial phenotyping. The company offers comprehensive
single-cell imaging solutions that allow researchers to phenotype
cells with spatial context and visualize how they organize and
interact to influence disease progression and response to therapy.
Akoya offers a full continuum of spatial phenotyping solutions to
serve the diverse needs of researchers across discovery,
translational and clinical research via its key platforms:
PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more
about Akoya, visit www.akoyabio.com.
Investor Contact:Priyam ShahSr. Director,
Investor RelationsAkoya Biosciences, Inc.investors@akoyabio.com
Media Contact:Christine Quern(617)
650-8497media@akoyabio.com
Grafico Azioni Akoya BioSciences (NASDAQ:AKYA)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Akoya BioSciences (NASDAQ:AKYA)
Storico
Da Giu 2023 a Giu 2024